Nine Point Average Drop After Eight Weeks on Supplement
Incline Village, NV, October 10, 2007 – According to a recent study published in the January 2007 issue of Journal of Clinical Hypertension, Juvenon™ helped reduce blood pressure in men 55 and older suffering from hypertension.
During the study, which was conducted at Boston Medical Center, 36 men over age 55 with hypertension were put on an 8-week regimen of Juvenon, a health supplement that slows the effects of aging on a cellular level. After eight weeks, the men saw an average 9-point drop in blood pressure. Juvenon did not lower blood pressure in men in the study with normal blood pressure.
Women Juvenon users have also reported positive affects on blood pressure. “Since taking Juvenon, there’s been a 20 point drop in my systolic pressure from the high 140s,” stated Nancy D., 54, of Massachusetts “We’ve had a history of high blood pressure on my father’s side.”
Juvenon utilizes a patented combination of alpha-lipoic acid and acetyl-L-carnitine to recharge the body’s mitochondria — the cellular ‘power plants’ that lose efficiency as the body ages. It consists of natural substances the body normally manufactures at sufficient levels for maximum health in youth but in insufficient quantities as we age. The patented composition of normal mitochondrial metabolites has been shown in laboratory experiments to support mitochondrial function as cells age by maintaining the membrane potential, promoting metabolism and cell function and enhancing anti-oxidative protection.
Hypertension remains the most prevalent form of cardiovascular disease, and there is a growing need for new and well-tolerated therapeutic approaches. While additional studies are needed to confirm results, it appears that mitochondrial dysfunction contributes to the origination and development of hypertension, and that therapy such as Juvenon, designed to restore mitochondrial function, could prove useful for patient management. For the complete study see the attachment.
The Science Behind Juvenon
Juvenon was developed by a team of nationally renowned biochemists from the University of California. Research was led by Dr. Bruce Ames, a specialist in cellular science for over 50 years and recognized in the 1970s for developing ways to identify potential carcinogens. The “Ames Test” became the world’s most widely used and respected method.
In the mid-1990s, developed an idea to slow the aging process. A dietary supplement called acetyl-L-carnitine – a naturally occurring biochemical that helped transport fatty acids into the cells and produce energy, was sweeping the country as the latest pick-me-up.
Back in his lab in California, Ames experimented with acetyl-L-carnitine in older rats and within weeks they were reenergized and their biochemistry was running more smoothly. But acetyl-L-carnitine also increased the level of free radicals, so Ames added lipoic acid, with astounding results.
Ames translated his research on acetyl-L-carnitine and lipoic acid into a tablet, Juvenon. In 1999, he and colleague Dr. Tony Hagen, now a professor at the Linus Pauling Institute at Oregon State University, founded the company to market the energy formula as a dietary supplement. Juvenon combines the two supplements into one pill to ensure the correct dosage. While Ames and Hagen’s company licenses the supplement, the University of California holds the patent. Ames does not accept any income from Juvenon — the university receives a third with another third to its department of molecular and cell biology, where he remains a professor.